Brianne Gardner at Raymond James
Member since: Sep '22 · 257 Opinions
A note regarding shock events: Going back to the 1940's the average return after a shock event is up 7 1/2% 12 months later. She sees good growth with its powerful AI centres and increasing revenue. It is in the volatile tech space and trades at a premium of 60X earnings. It has long term contracts with revenue growth of 40% year over year. However she sees a downside price of 25% and there has been some insider selling.
Although she doesn't own it she has traded it. She is cautious on the run-up and AI sector but it could show good growth and there is still room to run in the sector. It scores 8 out of 10 fundamentally. There is a mix of buy and hold on the street and analysts see an upside of 12 to 13% in valuation. You could keep holding it but also do some trimming.
It is one of the most integrated companies in U.S. health care. They thought it was very oversold so they doubled down on their position and will trend back. She is looking for 13 to 16% long term upside but doesn't consider it a buy and hold. Should be a high quality compounder.